Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)
141.02 x 1 143.00 x 1
Post-market by (Cboe BZX)
142.43 +3.27 (+2.35%) 03/26/25 [NASDAQ]
141.02 x 1 143.00 x 1
Post-market 142.80 +0.37 (+0.26%) 16:36 ET
Quote Overview for Wed, Mar 26th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
139.16
Day High
142.96
Open 139.34
Previous Close 139.16 139.16
Volume 1,514,600 1,514,600
Avg Vol 1,817,265 1,817,265
Stochastic %K 13.18% 13.18%
Weighted Alpha -35.36 -35.36
5-Day Change +1.00 (+0.71%) +1.00 (+0.71%)
52-Week Range 128.51 - 238.00 128.51 - 238.00
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,369,544
  • Shares Outstanding, K 146,375
  • Annual Sales, $ 9,676 M
  • Annual Income, $ 1,632 M
  • EBIT $ 2,696 M
  • EBITDA $ 3,660 M
  • 60-Month Beta 0.01
  • Price/Sales 2.14
  • Price/Cash Flow 6.13
  • Price/Book 1.23

Options Overview Details

View History
  • Implied Volatility 30.93% ( -3.66%)
  • Historical Volatility 30.02%
  • IV Percentile 41%
  • IV Rank 36.40%
  • IV High 47.65% on 07/25/24
  • IV Low 21.36% on 09/10/24
  • Put/Call Vol Ratio 0.29
  • Today's Volume 1,947
  • Volume Avg (30-Day) 4,604
  • Put/Call OI Ratio 1.18
  • Today's Open Interest 83,872
  • Open Int (30-Day) 81,204

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 33 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 3.59
  • Number of Estimates 25
  • High Estimate 4.23
  • Low Estimate 2.41
  • Prior Year 3.67
  • Growth Rate Est. (year over year) -2.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
138.38 +2.93%
on 02/28/25
Period Open: 140.49
157.09 -9.33%
on 03/10/25
+1.94 (+1.38%)
since 02/26/25
3-Month
128.51 +10.83%
on 02/12/25
Period Open: 149.90
157.09 -9.33%
on 03/10/25
-7.47 (-4.98%)
since 12/26/24
52-Week
128.51 +10.83%
on 02/12/25
Period Open: 212.02
238.00 -40.16%
on 07/12/24
-69.59 (-32.82%)
since 03/26/24

Most Recent Stories

More News
3 Value Stocks Walking a Fine Line

3 Value Stocks Walking a Fine Line

MTW : 9.46 (-0.84%)
SGH : 20.85 (+0.43%)
BIIB : 142.43 (+2.35%)
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

BIIB : 142.43 (+2.35%)
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

SRPT : 72.88 (-0.99%)
BMRN : 71.48 (-0.07%)
ABBV : 201.30 (-0.02%)
MRNA : 31.48 (-7.00%)
BIIB : 142.43 (+2.35%)
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

BMRN : 71.48 (-0.07%)
VRTX : 500.28 (-1.72%)
MRNA : 31.48 (-7.00%)
UTHR : 310.82 (-1.87%)
BIIB : 142.43 (+2.35%)
How Is Biogen's Stock Performance Compared to Other Biotech Stocks?

Despite Biogen's underperformance compared to other biotech stocks over the past year, analysts remain moderately optimistic about its future prospects.

GILD : 109.27 (+1.28%)
XBI : 85.08 (-2.30%)
BIIB : 142.43 (+2.35%)
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

BIIB : 142.43 (+2.35%)
3 Reasons BIIB is Risky and 1 Stock to Buy Instead

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

WING : 220.37 (+0.13%)
BIIB : 142.43 (+2.35%)
Is This the Most Undervalued Biotech Stock You Can Buy Right Now?

Biotech stock BIIB looks undervalued, but the company is also expected to deliver sluggish growth against declining revenues.

BIIB : 142.43 (+2.35%)
Biogen Stock Outlook: Is Wall Street Bullish or Bearish?

Biogen has lagged well behind the broader market over the past year, yet analysts maintain a fairly optimistic outlook on its future performance.

$SPX : 5,712.20 (-1.12%)
IBRN : 23.30 (-1.38%)
PIPR : 263.58 (-1.97%)
BIIB : 142.43 (+2.35%)
2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

$SPX : 5,712.20 (-1.12%)
STOK : 7.40 (-4.39%)
ACAD : 17.03 (-0.47%)
PHAT : 6.42 (+0.47%)
BIIB : 142.43 (+2.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 147.67
2nd Resistance Point 145.32
1st Resistance Point 143.87
Last Price 142.43
1st Support Level 140.07
2nd Support Level 137.72
3rd Support Level 136.27

See More

52-Week High 238.00
Fibonacci 61.8% 196.18
Fibonacci 50% 183.26
Fibonacci 38.2% 170.34
Last Price 142.43
52-Week Low 128.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies